Format

Send to

Choose Destination
Cytokine Growth Factor Rev. 2013 Jun;24(3):285-95. doi: 10.1016/j.cytogfr.2013.03.003. Epub 2013 Mar 29.

The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis.

Author information

1
Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia. mark.hedger@monash.edu

Abstract

The activins, as members of the transforming growth factor-β superfamily, are pleiotrophic regulators of cell development and function, including cells of the myeloid and lymphoid lineages. Clinical and animal studies have shown that activin levels increase in both acute and chronic inflammation, and are frequently indicators of disease severity. Moreover, inhibition of activin action can reduce inflammation, damage, fibrosis and morbidity/mortality in various disease models. Consequently, activin A and, more recently, activin B are emerging as important diagnostic tools and therapeutic targets in inflammatory and fibrotic diseases. Activin antagonists such as follistatin, an endogenous activin-binding protein, offer considerable promise as therapies in conditions as diverse as sepsis, liver fibrosis, acute lung injury, asthma, wound healing and ischaemia-reperfusion injury.

KEYWORDS:

Activin; Fibrosis; Follistatin; Immunoregulation; Inflammation

PMID:
23541927
DOI:
10.1016/j.cytogfr.2013.03.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center